查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011248

獸用疫苗市場：按產品類型、目標動物、給藥途徑、疾病類型和分銷管道分類的全球市場預測，2026-2032年

Veterinary Vaccines Market by Product Type, Animal Type, Route Of Administration, Disease Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，獸用疫苗市場價值將達到 150.5 億美元，到 2026 年將成長至 160.4 億美元，到 2032 年將達到 241.5 億美元，複合年成長率為 6.99%。

主要市場統計數據
基準年 2025 150.5億美元
預計年份：2026年 160.4億美元
預測年份 2032 241.5億美元
複合年成長率 (%) 6.99%

一份引人入勝且全面的介紹，概述了獸用疫苗的現狀、主要需求促進因素、技術變革以及全球相關人員的戰略重點。

獸用疫苗領域涉及生物技術、動物福利和全球貿易動態的交匯點，牽涉到從研究機構到獸醫診所的眾多相關人員。本導言概述了影響短期決策的核心主題：抗原設計和遞送方面的科學創新、物種間疾病負擔的波動以及依賴低溫運輸的生技藥品的實際操作。透過說明觀點和商業性觀點，讀者將獲得將實驗室進展轉化為臨床成果和供應鏈執行的實用指南。

快速的技術創新、動物健康領域的模式轉移、不斷發展的法規結構以及新的經營模式正在重塑獸用疫苗的格局和價值鏈。

獸用疫苗領域正經歷一場變革，背後是多種因素的複雜相互作用。分子生物學和載體工程的進步正在加速開發新一代疫苗平台，例如次單元、重組疫苗和病毒載體疫苗，從而拓展了控制複雜病毒和寄生蟲疾病的工具庫。同時，佐劑科學和製劑技術的進步使得疫苗產品更加穩定，劑量也得以降低，這影響著疫苗的物流、給藥方案的製定以及獸醫的採納。

評估美國於 2025 年實施的進口關稅對進口、供應連續性、價格趨勢和下游獸醫服務的累積營運、成本和貿易影響。

2025年實施的貿易措施和關稅調整為獸用疫苗生產中生物製藥和輔助材料的全球供應鏈帶來了新的摩擦。這些措施改變了進口原料的成本計算方式，特別是試劑、特殊黏合劑、一次性組件以及此前關稅負擔低且跨境流通的成品。為此，生產商和經銷商正在重新審視籌資策略，加快供應商認證計劃，並探索關鍵供應鏈的地域多角化，以降低貿易相關成本波動帶來的風險。

詳細的細分洞察揭示了產品類型、動物類別、給藥途徑、目標疾病和分銷管道如何全面影響臨床引入和商業策略。

深入了解市場區隔對於使產品策略與臨床需求和商業性可行性相符至關重要。按產品類型分類，該領域包括去活化疫苗、減毒活病毒疫苗、次單元疫苗和重組疫苗以及病毒載體疫苗，每種疫苗都有其自身的研發計劃、安全性以及低溫運輸的依賴性，這些因素都會影響市場進入的選擇。依動物種類分類，市場分為伴侶動物和牲畜。在伴侶動物領域，貓和狗是主要目標市場，重點在於便利性、安全性和飼主主導的購買行為。在牲畜領域，牛、家禽、羊和豬的群體疾病管制是首要任務，規模經濟和監管監督會影響疫苗的普及趨勢。

區域分析重點在於美洲、歐洲、中東和非洲以及亞太地區的差異化需求促進因素、監管細微差別、製造地和分銷挑戰。

地理因素對疫苗研發重點、監管策略和分銷方式有顯著影響。在美洲，完善的獸醫基礎設施、較高的寵物飼養率和成熟的商業管道正在推動高級產品和數位化分銷模式的快速普及。該地區的生產商日益重視生命週期數據和上市後安全性監測，同時利用先進的低溫運輸物流來支援複雜的生物製藥。

分析主要研發公司、生技藥品製造商、契約製造製造商、經銷商和服務供應商之間的競爭與合作趨勢，有助於制定策略定位和創新策略。

獸用疫苗產業的競爭動態是由那些兼具研發深度、生產規模和分銷網路的企業所塑造。一條策略軸線將那些大力投資於專有平台技術和產品線多樣性的企業與那些專注於特定適應症或合約服務（例如填充、包裝和低溫運輸物流）的企業區分開來。夥伴關係和授權協議是彌合能力差距的常用機制。以研發為導向的企業通常與大規模製造商合作以加速市場准入，而區域經銷商和臨床網路則提供市場滲透能力。

為產業領導者提供具有重大影響的策略建議，以加速疫苗創新、增強供應韌性、最佳化市場進入並提高所有管道的商業性可行性。

領導者應優先採取一系列切實可行且影響深遠的措施，以應對當前環境並抓住機會。首先，投資於平台的多功能性和模組化生產能力，使其能夠快速重新配置以適應不同的抗原類型和劑型。這將縮短臨床試驗時間並支援區域生產策略。其次，加強供應商多元化和合格計劃，以降低關稅相關的採購風險。這包括與合格的契約製造以及本地灌裝和包裝合作夥伴建立合作關係，以確保即使在貿易政策波動的情況下也能保持業務的連續性。

為了確保分析的有效性和可重複性，我們採用了一種穩健的混合調查方法，結合了與主要相關人員的對話、二手文獻的整合以及嚴格的數據三角測量。

本研究採用混合方法，旨在兼顧深度與效度。主要研究包括對科學領導者、監管專家、製造企業高管和分銷合作夥伴進行結構化訪談，以確定實際限制因素和前瞻性優先事項。這些定性見解指南了後續的針對性研究，以確定主題優先事項並闡明技術依賴性和商業性考慮。除主要資料外，廣泛整契約儕審查文獻、監管指導文件和行業白皮書，為平台和疾病特異性分析提供了技術基礎。

簡要概述了高階決策者在應對不斷變化的動物疫苗生態系統時應關注的策略要點、未解決的問題和短期優先事項。

本分析整合了技術進步、監管政策變化、市場區隔現狀、區域趨勢以及貿易政策變動對動物疫苗產業的策略影響。主要結論包括：需要在創新與業務永續營運之間取得平衡；區域生產和分銷靈活性具有戰略價值；以及基於市場細分的產品策略至關重要，這些策略應反映伴侶動物市場和牲畜市場的差異。總體而言，這些發現表明，對平台和供應鏈多元化以及監管參與進行戰術性投資，可以在市場進入和臨床應用方面帶來顯著回報。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 獸用疫苗市場：依產品類型分類

  • 去活化疫苗
  • 減毒活病毒疫苗
  • 次單元疫苗和重組疫苗
  • 病毒載體疫苗

第9章 獸用疫苗市場：依動物類型分類

  • 伴侶動物
    • 貓
    • 狗
  • 家畜
    • 牛
    • 家禽
    • 羊
    • 豬

第10章 獸用疫苗市場：依給藥途徑分類

  • 口服
  • 腸外
  • 外用

第11章 獸用疫苗市場：依疾病類型分類

  • 細菌感染疾病
    • 梭狀芽孢桿菌
    • 大腸桿菌
    • 鉤端螺旋體病
    • 巴斯德氏菌
  • 黴菌感染疾病
  • 寄生蟲感染疾病
    • 體外寄生蟲
    • 體內寄生蟲
  • 病毒感染疾病
    • 禽流感病毒
    • 牛病毒性腹瀉病毒（BVDV）
    • 口蹄疫病毒（FMDV）
    • 新城疫病毒
    • 豬繁殖與呼吸綜合症病毒（PRRSV）
    • 狂犬病毒

第12章 獸用疫苗市場：依通路分類

  • 網路藥房
  • 零售藥房
  • 動物醫院

第13章 獸用疫苗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 獸用疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 獸用疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國獸用疫苗市場

第17章：中國獸用疫苗市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Arko Corp.
  • Bimeda Biologicals Inc
  • Biogenesis Bago SA
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Endovac Animal Health
  • Hester Biosciences Limited
  • Hipra SA
  • Huvepharma, Inc.
  • Indian Immunologicals Ltd.
  • Kemin Industries, Inc.
  • Merck & Co., Inc.
  • Neogen Corporation
  • Pfizer, Inc.
  • Phibro Animal Health Corporation
  • SAN Group Biotech Germany GmbH
  • Seppic by Air Liquide Healthcare
  • SK Bioscience
  • Vaxxinova
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-4316E4E89380

The Veterinary Vaccines Market was valued at USD 15.05 billion in 2025 and is projected to grow to USD 16.04 billion in 2026, with a CAGR of 6.99%, reaching USD 24.15 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.05 billion
Estimated Year [2026] USD 16.04 billion
Forecast Year [2032] USD 24.15 billion
CAGR (%) 6.99%

A compelling, comprehensive introduction that frames the current state of veterinary vaccines, key demand drivers, technological inflections, and strategic priorities for stakeholders globally

The veterinary vaccines domain sits at the intersection of biotechnology, animal welfare, and global trade dynamics, with stakeholders ranging from research laboratories to frontline veterinary practices. This introduction frames the core themes that drive near-term decision-making: scientific innovation in antigen design and delivery, shifting disease burdens across species, and the operational realities of cold-chain dependent biologics. By grounding the narrative in both scientific and commercial perspectives, readers gain a practical orientation that links laboratory advances to clinic-level outcomes and supply-chain execution.

In addition, the introduction outlines the primary levers that influence program viability and adoption. These include evolving regulatory expectations for immunogenicity and safety, the economics of companion animal versus livestock interventions, and the role of distribution networks in ensuring timely access. Taken together, the early section establishes the analytical lens used throughout the study, emphasizing actionable insights over abstract trends and setting expectations for how subsequent analysis will translate into strategic choices for R&D, manufacturing, and commercial teams.

How rapid technological innovation, shifting animal health paradigms, evolving regulatory frameworks, and new commercial models are together reshaping the veterinary vaccines landscape and value chains

The landscape of veterinary vaccines is undergoing a period of transformative change driven by multiple, interlocking forces. Advances in molecular biology and vector engineering have accelerated the development of next-generation platforms such as subunit, recombinant, and viral vector approaches, expanding the toolkit available to control complex viral and parasitic diseases. Concurrently, improvements in adjuvant science and formulation technologies are enabling more stable products with reduced dosing requirements, which in turn affect logistics, dosing regimens, and uptake among practitioners.

At the same time, regulatory authorities are adapting frameworks to accommodate novel modalities and expedited pathways for high-priority animal health threats. This regulatory evolution is producing both opportunities and complexities: faster pathways for certain constructs are balanced by heightened expectations for post-market surveillance and batch-release data. Commercially, digital veterinary services and online distribution channels are reshaping how vaccines reach end users, with telemedicine and e-commerce altering demand patterns for companion animal vaccines and creating alternate routes to market. Finally, growing emphasis on One Health perspectives is aligning public and private priorities around zoonotic risk mitigation, which increases collaboration across human and animal health domains and elevates investment in vaccines that reduce cross-species transmission.

Assessing the cumulative operational, cost and trade impacts of the United States tariffs enacted in 2025 on imports, supply continuity, pricing dynamics, and downstream veterinary services

The imposition of trade measures and tariff adjustments in 2025 introduced new friction into global supply chains for biologics and ancillary materials used in veterinary vaccine manufacture. These measures have changed the calculus for imported inputs, particularly reagents, specialty adhesives, single-use components, and finished-dose products that historically moved across borders with lower tariff exposure. In response, manufacturers and distributors have reassessed sourcing strategies, accelerated supplier qualification programs, and explored regionalization of critical supply lines to reduce vulnerability to trade-related cost volatility.

Operationally, the tariffs have amplified the importance of local manufacturing capacity and warehousing agility. Firms with pre-existing regional production hubs were able to mitigate exposure more effectively, whereas organizations reliant on long-haul imports faced longer lead times and higher landed costs. The policy environment has also encouraged contractual renegotiations and greater use of hedging strategies for currency and procurement. For clinical and commercial teams, the practical outcome has been a renewed focus on prioritizing product portfolios for geographies where supply reliability and cost predictability can be maintained, while exploring partnerships and licensing that allow for localized fill-finish and distribution to preserve market access under changing trade regimes.

Deep segmentation insights revealing how product types, animal categories, administration routes, disease targets, and distribution channels collectively inform clinical adoption and commercial strategies

A nuanced understanding of market segmentation is essential to align product strategy with clinical need and commercial feasibility. Based on product type, the domain includes Inactivated Vaccines, Live Attenuated Vaccines, Subunit & Recombinant Vaccines, and Viral Vector Vaccines, each presenting distinct development timelines, safety profiles, and cold-chain dependencies that influence go-to-market choices. When examined by animal type, the market divides between Companion Animals and Livestock Animals; companion animal work largely concentrates on Cats and Dogs with emphasis on convenience, safety and owner-driven purchasing behavior, while livestock efforts prioritize herd-level disease control across Cattle, Poultry, Sheep, and Swine with scale efficiencies and regulatory oversight shaping adoption dynamics.

Route of administration introduces further differentiation, with Oral, Parenteral, and Topical delivery pathways offering varying trade-offs between ease of administration, immune response quality, and formulation complexity. Disease-type considerations add another strategic layer: vaccines targeting Bacterial Infections, Fungal Infections, Parasitic Infections, and Viral Infections must be designed and communicated differently. Bacterial indications encompass Clostridial illness, E. coli syndromes, Leptospirosis, and Pasteurella, each requiring targeted antigens and often adjuvant optimization. Parasitic disease work addresses both Ectoparasites and Endoparasites, where vaccine-induced protection must be balanced against environmental and management controls. Viral vaccine targets range from Avian Influenza Virus to Bovine Viral Diarrhea Virus, Foot-and-Mouth Disease Virus, Newcastle Disease Virus, Porcine Reproductive & Respiratory Syndrome Virus, and Rabies Virus, each presenting unique immunological challenges and regulatory considerations. Finally, distribution channel dynamics across Online Pharmacies, Retail Pharmacies, and Veterinary Clinics shape commercial execution: direct clinic distribution favors practitioner influence and cold-chain stewardship, retail pharmacies offer consumer convenience, and online pharmacies create new purchasing pathways that require digital logistics and trust-building for vaccine products.

Region-focused intelligence highlighting differentiated demand drivers, regulatory nuances, manufacturing hubs, and distribution challenges across the Americas, EMEA, and Asia-Pacific regions

Geographic dynamics materially influence vaccine development priorities, regulatory strategy, and distribution approaches. In the Americas, strong veterinary infrastructure, high companion animal ownership rates, and established commercial channels favor rapid adoption of premium products and digital distribution models. Producers in this region increasingly emphasize lifecycle data and post-market safety monitoring while leveraging sophisticated cold-chain logistics to support complex biologics.

Across Europe, Middle East & Africa, regulatory harmonization efforts coexist with wide heterogeneity in manufacturing capacity and purchasing power. This region demands flexible strategies that accommodate stringent regulatory expectations in some markets alongside capacity-building and cost-sensitive models in others. Meanwhile, Asia-Pacific reflects a mix of large-scale livestock production systems, emergent manufacturing hubs, and rising companion animal ownership that together create both high-volume opportunities and the need for scalable, locally adapted supply solutions. Across all regions, local regulatory pathways, import controls, and distribution infrastructures remain decisive factors in the commercial planning and rollout of new veterinary vaccine products.

Competitive and collaborative behavior analysis among leading developers, biologics formulators, contract manufacturers, distributors, and service providers shaping strategic positioning and innovation

Competitive dynamics in the veterinary vaccines space are shaped by companies that combine R&D depth, manufacturing scale, and distribution reach. One strategic axis separates organizations that invest heavily in proprietary platform technologies and pipeline diversity from those that focus on niche indications or contract services such as fill-finish and cold-chain logistics. Partnerships and licensing agreements serve as common mechanisms to bridge capability gaps: research-focused entities frequently collaborate with large-scale manufacturers to expedite commercial access, while regional distributors and clinical networks provide market penetration capacity.

Another important trend is the increasing role of contract manufacturing and specialized biologics service providers that enable smaller innovators to scale without extensive capital investment. These arrangements influence time-to-market and create modular paths to commercialization, especially for subunit and viral vector constructs that demand specific process expertise. From a commercial strategy perspective, companies that align clinical evidence generation with pragmatic distribution models-ensuring appropriate packaging, labeling and cold-chain integrity for end users-tend to achieve better practitioner acceptance and uptake. Finally, collaborative initiatives that address cross-cutting challenges such as cold-chain standardization, regulatory harmonization, and post-market surveillance are becoming more prominent as the industry seeks efficiencies across the value chain.

High-impact strategic recommendations for industry leaders to accelerate vaccine innovation, strengthen supply resilience, optimize market access, and improve commercial execution across channels

Leaders should prioritize a set of pragmatic, high-impact measures to navigate the current environment and capture opportunity. First, invest in platform versatility and modular manufacturing capabilities that allow rapid reconfiguration for different antigen types and dosing formats; this reduces time-to-clinic and supports regional production strategies. Second, strengthen supplier diversification and qualification programs to mitigate tariff-driven sourcing risks, including building relationships with qualified contract manufacturers and local fill-finish partners to preserve continuity under shifting trade policies.

Third, align regulatory strategies early with target market requirements and plan for robust post-market surveillance to satisfy evolving safety expectations; engaging with regulators through parallel consultations can shorten approval pathways for innovative modalities. Fourth, optimize commercial models by tailoring distribution approaches for companion animal versus livestock channels, integrating digital sales and telemedicine where appropriate, and ensuring field-level training for veterinarians and paraprofessionals to improve administration and compliance. Lastly, pursue collaborative initiatives that advance cold-chain resilience and shared data platforms for adverse event monitoring, which will enhance stakeholder confidence and support more rapid adoption of next-generation vaccines.

Robust mixed-methods research methodology combining primary stakeholder engagement, secondary literature synthesis, and rigorous data triangulation to ensure analytical validity and reproducibility

The research underpinning this study follows a mixed-methods approach designed to balance depth and validity. Primary engagement included structured interviews with scientific leaders, regulatory specialists, manufacturing executives, and distribution partners to surface practical constraints and forward-looking priorities. These qualitative inputs informed thematic priorities and guided targeted follow-ups that clarified technical dependencies and commercial considerations. Alongside primary input, an extensive synthesis of peer-reviewed literature, regulatory guidance documents, and industry whitepapers provided the technical foundation for platform-specific and disease-targeted analysis.

Data triangulation was applied to reconcile differences across sources and to validate inferred conclusions. Where possible, technical assertions were corroborated by multiple independent stakeholders to reduce bias. The methodology emphasizes transparency in assumptions and documents analytical boundaries, including the exclusion of speculative forecasts or proprietary financial metrics. In addition, the study incorporated iterative reviews by subject matter experts to ensure that clinical, manufacturing, and commercial interpretations remain robust and aligned with current practice.

Concise synthesis of strategic takeaways, unresolved challenges, and near-term priorities that senior decision-makers should act on to navigate the evolving animal vaccine ecosystem

This analysis synthesizes the strategic implications of technological progress, regulatory evolution, segmentation realities, regional dynamics, and trade policy shifts for the veterinary vaccines sector. Key takeaways include the imperative to balance innovation with operational resilience, the strategic value of regional manufacturing and distribution agility, and the importance of segmentation-informed product strategies that reflect differences between companion animal and livestock markets. Collectively, these insights underscore that tactical investments in platforms, supply chain diversity, and regulatory engagement deliver outsized returns in market access and clinical uptake.

Looking ahead, decision-makers should treat vaccine development not as a linear product project but as an ecosystem challenge that integrates science, manufacturing, regulation, and field execution. By doing so, organizations can better align R&D investments to practical adoption pathways, reduce exposure to external shocks, and accelerate the translation of scientific advances into measurable animal health outcomes. The conclusion therefore reinforces the need for integrated, cross-functional approaches that convert technical advances into durable commercial advantage.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Vaccines Market, by Product Type

  • 8.1. Inactivated Vaccines
  • 8.2. Live Attenuated Vaccines
  • 8.3. Subunit & Recombinant Vaccines
  • 8.4. Viral Vector Vaccines

9. Veterinary Vaccines Market, by Animal Type

  • 9.1. Companion Animals
    • 9.1.1. Cats
    • 9.1.2. Dogs
  • 9.2. Livestock Animals
    • 9.2.1. Cattle
    • 9.2.2. Poultry
    • 9.2.3. Sheep
    • 9.2.4. Swine

10. Veterinary Vaccines Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral
  • 10.3. Topical

11. Veterinary Vaccines Market, by Disease Type

  • 11.1. Bacterial Infections
    • 11.1.1. Clostridial
    • 11.1.2. E. Coli
    • 11.1.3. Leptospirosis
    • 11.1.4. Pasteurella
  • 11.2. Fungal Infections
  • 11.3. Parasitic Infections
    • 11.3.1. Ectoparasites
    • 11.3.2. Endoparasites
  • 11.4. Viral Infections
    • 11.4.1. Avian Influenza Virus
    • 11.4.2. Bovine Viral Diarrhea Virus (BVDV)
    • 11.4.3. Foot-and-Mouth Disease Virus (FMDV)
    • 11.4.4. Newcastle Disease Virus
    • 11.4.5. Porcine Reproductive & Respiratory Syndrome Virus (PRRSV)
    • 11.4.6. Rabies Virus

12. Veterinary Vaccines Market, by Distribution Channel

  • 12.1. Online Pharmacies
  • 12.2. Retail Pharmacies
  • 12.3. Veterinary Clinics

13. Veterinary Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Veterinary Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Veterinary Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Veterinary Vaccines Market

17. China Veterinary Vaccines Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Arko Corp.
  • 18.6. Bimeda Biologicals Inc
  • 18.7. Biogenesis Bago S.A.
  • 18.8. Boehringer Ingelheim International GmbH
  • 18.9. Ceva Sante Animale
  • 18.10. Dechra Pharmaceuticals PLC
  • 18.11. Elanco Animal Health Incorporated
  • 18.12. Endovac Animal Health
  • 18.13. Hester Biosciences Limited
  • 18.14. Hipra S.A.
  • 18.15. Huvepharma, Inc.
  • 18.16. Indian Immunologicals Ltd.
  • 18.17. Kemin Industries, Inc.
  • 18.18. Merck & Co., Inc.
  • 18.19. Neogen Corporation
  • 18.20. Pfizer, Inc.
  • 18.21. Phibro Animal Health Corporation
  • 18.22. SAN Group Biotech Germany GmbH
  • 18.23. Seppic by Air Liquide Healthcare
  • 18.24. SK Bioscience
  • 18.25. Vaxxinova
  • 18.26. Virbac S.A.
  • 18.27. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VETERINARY VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VETERINARY VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VETERINARY VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY VACCINES MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY VACCINES MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY VACCINES MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SHEEP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SHEEP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SHEEP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY VACCINES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY VACCINES MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY VACCINES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY VACCINES MARKET SIZE, BY E. COLI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY VACCINES MARKET SIZE, BY E. COLI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY VACCINES MARKET SIZE, BY E. COLI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PASTEURELLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PASTEURELLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PASTEURELLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ECTOPARASITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ECTOPARASITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ECTOPARASITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ENDOPARASITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ENDOPARASITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ENDOPARASITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RABIES VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RABIES VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RABIES VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS VETERINARY VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL VETERINARY VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. GCC VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GCC VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. GCC VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. GCC VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 219. GCC VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. GCC VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. GCC VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 223. GCC VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 224. GCC VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 225. GCC VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. G7 VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. G7 VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. G7 VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. G7 VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 252. G7 VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 253. G7 VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. G7 VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. G7 VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 256. G7 VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 257. G7 VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 258. G7 VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. NATO VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. NATO VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. NATO VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. NATO VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 263. NATO VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 264. NATO VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 265. NATO VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. NATO VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 267. NATO VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 268. NATO VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 269. NATO VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)